Microbiome-derived metabolite effects on intestinal barrier integrity and immune cell response to infection
Microbiology · 11.10.2024 · 170 (10)
DOI: 10.1099/mic.0.001504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology, erschienen am 11.10.2024. Verfasst von Lauren Adams und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Infection and Immunology, College of Medical, Veterinary and Life Sciences, Sir Graeme Davies Building, University of Glasgow, Glasgow, G12…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Intestinal Mucosa, Escherichia coli. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
The gut microbiota exerts a significant influence on human health and disease. While compositional changes in the gut microbiota in specific diseases can easily be determined, we lack a detailed mechanistic understanding of how these changes exert effects at the cellular level. However, the putative local and systemic effects on human physiology that are attributed to the gut microbiota are clearly being mediated through molecular communication. Here, we determined the effects of gut microbiome-derived metabolites l -tryptophan, butyrate, trimethylamine (TMA), 3-methyl-4-(trimethylammonio)butanoate (3,4-TMAB), 4-(trimethylammonio)pentanoate (4-TMAP), ursodeoxycholic acid (UDCA), glycocholic acid (GCA) and benzoate on the first line of defence in the gut. Using in vitro models of intestinal barrier integrity and studying the interaction of macrophages with pathogenic and non-pathogenic bacteria, we could ascertain the influence of these metabolites at the cellular level at physiologically relevant concentrations. Nearly all metabolites exerted positive effects on barrier function, but butyrate prevented a reduction in transepithelial resistance in the presence of the pathogen Escherichia coli , despite inducing increased apoptosis and exerting increased cytotoxicity. Induction of IL-8 was unaffected by all metabolites, but GCA stimulated increased intra-macrophage growth of E. coli and tumour necrosis-alpha (TNF-α) release. Butyrate, 3,4-TMAB and benzoate all increased TNF-α release independent of bacterial replication. These findings reiterate the complexity of understanding microbiome effects on host physiology and underline that microbiome metabolites are crucial mediators of barrier function and the innate response to infection. Understanding these metabolites at the cellular level will allow us to move towards a better mechanistic understanding of microbiome influence over host physiology, a crucial step in advancing microbiome research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Infection and Immunology, College of Medical, Veterinary and Life Sciences, Sir Graeme Davies Building, University of Glasgow, Glasgow, G12 8TA, UK.
- Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, CB4 0WG, UK.
Förderung
- Biotechnology and Biological Sciences Research Council
Zitieren
APA
Adams, L., Li, X., Burchmore, R., Goodwin, R. J. A., & Wall, D. M. (2024). Microbiome-derived metabolite effects on intestinal barrier integrity and immune cell response to infection. Microbiology, 170(10). https://doi.org/10.1099/mic.0.001504
Vancouver
Adams L, Li X, Burchmore R, Goodwin RJA, Wall DM. Microbiome-derived metabolite effects on intestinal barrier integrity and immune cell response to infection. Microbiology. 2024;170(10). doi:10.1099/mic.0.001504
BibTeX
@article{Adams2024,
author = {Adams, Lauren and Li, Xiang and Burchmore, Richard and Goodwin, Richard J A and Wall, Daniel M},
title = {Microbiome-derived metabolite effects on intestinal barrier integrity and immune cell response to infection},
journal = {Microbiology},
year = {2024},
volume = {170},
number = {10},
doi = {10.1099/mic.0.001504}
}
EUVIMED